Tomivosertib hydrochloride is under clinical development by EFFECTOR Therapeutics and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer). According to GlobalData, Phase II drugs for Transitional Cell Cancer (Urothelial Cell Cancer) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tomivosertib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tomivosertib hydrochloride overview
Tomivosertib hydrochloride (eFT-508) is under development for the treatment of solid tumors, metastatic breast cancer and hematological malignancies including lymphomas, non-small cell lung cancer and head and neck cancer, hepatocellular carcinoma, urothelial cell cancer, colon carcinoma and relapsed/refractory Acute Myeloid Leukemia (AML). The drug candidate is administered orally. It targets MKNK1 (MAP kinase-interacting serine/threonine-protein kinase) and MNK2. It is developed by using the structure-based and fragment-based drug design. It was also under development for the treatment of diffuse large B-cell lymphoma and triple-negative breast cancer.
See Also:
It was also under development for the treatment of microsatellite stable relapsed or refractory colorectal cancer and metastatic hormone-refractory prostate cancer.
EFFECTOR Therapeutics overview
eFFECTOR Therapeutics is a biopharmaceutical company that discovers and develops selective translation regulators (STRIs) for the treatment of cancer. It is investigating its lead product candidate Tomivosertib, an oral small molecule inhibitor of MNK in combination with inhibitors of PD-1 and programmed cell death ligand 1 (PD-L1) to treat metastatic non-small cell lung cancer (NSCLC) and solid tumors. The company is also evaluating Zotatifin, an antiviral agent against estrogen receptor (ER) positive breast cancer, KRAS mutant NSCLC, solid tumors, and SARS-CoV-2; and eIF4Ei for solid tumors. Its compounds focuses on restoring the translational control of processes by preserving normal cell function. eFFECTOR Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of Tomivosertib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
